Zobraziť v EDS

Allopurinol and blood pressure variability following ischemic stroke and transient ischemic attack: a secondary analysis of XILO-FIST

Uložené v:
Podrobná bibliografia
Názov: Allopurinol and blood pressure variability following ischemic stroke and transient ischemic attack: a secondary analysis of XILO-FIST
Autori: Alexander S. MACDONALD, Alex MCCONNACHIE, David Alexander DICKIE, Philip M. BATH, Kirsten FORBES, Terence QUINN, Niall M. BROOMFIELD, Krishna DANI, Alex DONEY, Keith W. MUIR, Allan STRUTHERS, Matthew WALTERS, Mark BARBER, Ajay BHALLA, Alan CAMERON, Paul GUYLER, Ahamad HASSAN, Mark KEARNEY, Breffni KEEGAN, Sekaran LAKSHMANAN, Mary Joan MACLEOD, Marc RANDALL, Louise SHAW, Ganesh SUBRAMANIAN, David WERRING, Jesse DAWSON
Prispievatelia: University of Aberdeen.Applied Medicine, University of Aberdeen.Cardiometabolic Disease, University of Aberdeen.Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen.Medical Sciences - Cardiovascular Group, University of Aberdeen.Institute of Medical Sciences
Zdroj: J Hum Hypertens
Informácie o vydavateľovi: Springer Science and Business Media LLC, 2024.
Rok vydania: 2024
Predmety: Supplementary Information, Allopurinol, Blood Pressure, R Medicine, Allopurinol/therapeutic use, name=Internal Medicine, Article, 03 medical and health sciences, 0302 clinical medicine, Blood Pressure Monitoring, Risk Factors, Ambulatory, Internal Medicine, Humans, Ischemic Stroke/complications, Ischemic Stroke, Transient/diagnostic imaging, Ischemic Attack, Blood Pressure Monitoring, Ambulatory, Uric Acid, Ischemic Attack, Transient, Hypertension, TSA BHF 2013/01, British Heart Foundation
Popis: Blood Pressure Variability (BPV) is associated with cardiovascular risk and serum uric acid level. We investigated whether BPV was lowered by allopurinol and whether it was related to neuroimaging markers of cerebral small vessel disease (CSVD) and cognition. We used data from a randomised, double-blind, placebo-controlled trial of two years allopurinol treatment after recent ischemic stroke or transient ischemic attack. Visit-to-visit BPV was assessed using brachial blood pressure (BP) recordings. Short-term BPV was assessed using ambulatory BP monitoring (ABPM) performed at 4 weeks and 2 years. Brain MRI was performed at baseline and 2 years. BPV measures were compared between the allopurinol and placebo groups, and with CSVD and cognition. 409 participants (205 allopurinol; 204 placebo) were included in the visit-to-visit BPV analyses. There were no significant differences found between placebo and allopurinol groups for any measure of visit-to-visit BPV. 196 participants were included in analyses of short-term BPV at week 4. Two measures were reduced by allopurinol: the standard deviation (SD) of systolic BP (by 1.30 mmHg (95% confidence interval (CI) 0.18–2.42, p = 0.023)); and the average real variability (ARV) of systolic BP (by 1.31 mmHg (95% CI 0.31–2.32, p = 0.011)). There were no differences in other measures at week 4 or in any measure at 2 years, and BPV was not associated with CSVD or cognition. Allopurinol treatment did not affect visit-to-visit BPV in people with recent ischemic stroke or TIA. Two BPV measures were reduced at week 4 by allopurinol but not at 2 years.
Druh dokumentu: Article
Other literature type
Popis súboru: application/pdf
Jazyk: English
ISSN: 1476-5527
DOI: 10.1038/s41371-024-00906-5
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38438602
https://discovery-pp.ucl.ac.uk/id/eprint/10189129/
Rights: CC BY
Prístupové číslo: edsair.doi.dedup.....b75e7cc4f6032cf7afc6595f4468f0f7
Databáza: OpenAIRE
Popis
Abstrakt:Blood Pressure Variability (BPV) is associated with cardiovascular risk and serum uric acid level. We investigated whether BPV was lowered by allopurinol and whether it was related to neuroimaging markers of cerebral small vessel disease (CSVD) and cognition. We used data from a randomised, double-blind, placebo-controlled trial of two years allopurinol treatment after recent ischemic stroke or transient ischemic attack. Visit-to-visit BPV was assessed using brachial blood pressure (BP) recordings. Short-term BPV was assessed using ambulatory BP monitoring (ABPM) performed at 4 weeks and 2 years. Brain MRI was performed at baseline and 2 years. BPV measures were compared between the allopurinol and placebo groups, and with CSVD and cognition. 409 participants (205 allopurinol; 204 placebo) were included in the visit-to-visit BPV analyses. There were no significant differences found between placebo and allopurinol groups for any measure of visit-to-visit BPV. 196 participants were included in analyses of short-term BPV at week 4. Two measures were reduced by allopurinol: the standard deviation (SD) of systolic BP (by 1.30 mmHg (95% confidence interval (CI) 0.18–2.42, p = 0.023)); and the average real variability (ARV) of systolic BP (by 1.31 mmHg (95% CI 0.31–2.32, p = 0.011)). There were no differences in other measures at week 4 or in any measure at 2 years, and BPV was not associated with CSVD or cognition. Allopurinol treatment did not affect visit-to-visit BPV in people with recent ischemic stroke or TIA. Two BPV measures were reduced at week 4 by allopurinol but not at 2 years.
ISSN:14765527
DOI:10.1038/s41371-024-00906-5